Affiliation:
1. Children's Cancer Institute Lowy Cancer Research Centre School of Clinical Medicine UNSW Medicine & Health Centre for Childhood Cancer Research UNSW Sydney Sydney New South Wales Australia
2. RTI International Research Triangle Park North Carolina USA
3. Verastem Oncology, Inc. Needham Massachusetts USA
4. National Cancer Institute Bethesda Maryland USA
Abstract
AbstractBackgroundAcute lymphoblastic leukemia (ALL) remains one of the most common causes of cancer‐related mortality in children. Phosphoinositide 3‐kinases (PI3Ks) are a family of lipid kinases, and aberrations in the PI3K pathway are associated with several hematological malignancies, including ALL. Duvelisib (Copiktra) is an orally available, small molecule dual inhibitor of PI3Kδ and PI3Kγ, that is Food and Drug Administration (FDA) approved for the treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Here, we report the efficacy of duvelisib against a panel of pediatric ALL patient‐derived xenografts (PDXs).ProceduresThirty PDXs were selected for a single mouse trial based on PI3Kδ (PIK3CD) and PI3Kγ (PIK3CG) expression and mutational status. PDXs were grown orthotopically in NSG (NOD.Cg‐PrkdcscidIL2rgtm1Wjl/SzJAusb) mice, and engraftment was evaluated by enumerating the proportion of human versus mouse CD45+ cells (%huCD45+) in the peripheral blood. Treatment commenced when the %huCD45+ reached greater than or equal to 1%, and events were predefined as %huCD45+ greater than or equal to 25% or leukemia‐related morbidity. Duvelisib was administered per oral (50 mg/kg, twice daily for 28 days). Drug efficacy was assessed by event‐free survival and stringent objective response measures.ResultsPI3Kδ and PI3Kγ mRNA expression was significantly higher in B‐lineage than T‐lineage ALL PDXs (p‐values <.0001). Duvelisib was well‐tolerated and reduced leukemia cells in the peripheral blood in four PDXs, but with only one objective response. There was no obvious relationship between duvelisib efficacy and PI3Kδ or PI3Kγ expression or mutation status, nor was the in vivo response to duvelisib subtype dependent.ConclusionsDuvelisib demonstrated limited in vivo activity against ALL PDXs.
Funder
National Cancer Institute
Subject
Oncology,Hematology,Pediatrics, Perinatology and Child Health
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献